Literature DB >> 34774569

Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.

Morgan E Meissner1, Nora A Willkomm1, Jamie Lucas1, William G Arndt1, Sarah F Aitken1, Emily J Julik1, Sunanda Baliga1, Louis M Mansky2.   

Abstract

Human immunodeficiency virus (HIV) mutagenesis is driven by a variety of internal and external sources, including the host APOBEC3 (apolipoprotein B mRNA editing enzyme catalytic polypetide-like 3; A3) family of mutagenesis factors, which catalyze G-to-A transition mutations during virus replication. HIV-2 replication is characterized by a relative lack of G-to-A mutations, suggesting infrequent mutagenesis by A3 proteins. To date, the activity of the A3 repertoire against HIV-2 has remained largely uncharacterized, and the mutagenic activity of these proteins against HIV-2 remains to be elucidated. In this study, we provide the first comprehensive characterization of the restrictive capacity of A3 proteins against HIV-2 in cell culture using a dual fluorescent reporter HIV-2 vector virus. We found that A3F, A3G, and A3H restricted HIV-2 infectivity in the absence of Vif and were associated with significant increases in the frequency of viral mutants. These proteins increased the frequency of G-to-A mutations within the proviruses of infected cells as well. A3G and A3H also reduced HIV-2 infectivity via inhibition of reverse transcription and the accumulation of DNA products during replication. In contrast, A3D did not exhibit any restrictive activity against HIV-2, even at higher expression levels. Taken together, these results provide evidence that A3F, A3G, and A3H, but not A3D, are capable of HIV-2 restriction. Differences in A3-mediated restriction of HIV-1 and HIV-2 may serve to provide new insights in the observed mutation profiles of these viruses.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cytidine deaminase; lentivirus; mutagenesis; restriction factor; retrovirus

Mesh:

Substances:

Year:  2021        PMID: 34774569      PMCID: PMC8752514          DOI: 10.1016/j.jmb.2021.167355

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  63 in total

1.  APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.

Authors:  Holly A Sadler; Mark D Stenglein; Reuben S Harris; Louis M Mansky
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

2.  G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo.

Authors:  Tara L Kieffer; Patty Kwon; Richard E Nettles; Yefei Han; Stuart C Ray; Robert F Siliciano
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  Fiji: an open-source platform for biological-image analysis.

Authors:  Johannes Schindelin; Ignacio Arganda-Carreras; Erwin Frise; Verena Kaynig; Mark Longair; Tobias Pietzsch; Stephan Preibisch; Curtis Rueden; Stephan Saalfeld; Benjamin Schmid; Jean-Yves Tinevez; Daniel James White; Volker Hartenstein; Kevin Eliceiri; Pavel Tomancak; Albert Cardona
Journal:  Nat Methods       Date:  2012-06-28       Impact factor: 28.547

4.  Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif.

Authors:  Anne Piantadosi; Daryl Humes; Bhavna Chohan; R Scott McClelland; Julie Overbaugh
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

5.  Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors.

Authors:  Shiv K Gandhi; Janet D Siliciano; Justin R Bailey; Robert F Siliciano; Joel N Blankson
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

6.  HIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation.

Authors:  Jonathan M O Rawson; Sean R Landman; Cavan S Reilly; Louis M Mansky
Journal:  Retrovirology       Date:  2015-07-10       Impact factor: 4.602

7.  Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity.

Authors:  Eric W Refsland; Judd F Hultquist; Elizabeth M Luengas; Terumasa Ikeda; Nadine M Shaban; Emily K Law; William L Brown; Cavan Reilly; Michael Emerman; Reuben S Harris
Journal:  PLoS Genet       Date:  2014-11-20       Impact factor: 5.917

8.  APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model.

Authors:  Kei Sato; Junko S Takeuchi; Naoko Misawa; Taisuke Izumi; Tomoko Kobayashi; Yuichi Kimura; Shingo Iwami; Akifumi Takaori-Kondo; Wei-Shau Hu; Kazuyuki Aihara; Mamoru Ito; Dong Sung An; Vinay K Pathak; Yoshio Koyanagi
Journal:  PLoS Pathog       Date:  2014-10-16       Impact factor: 6.823

Review 9.  APOBEC3G-Mediated G-to-A Hypermutation of the HIV-1 Genome: The Missing Link in Antiviral Molecular Mechanisms.

Authors:  Ayaka Okada; Yasumasa Iwatani
Journal:  Front Microbiol       Date:  2016-12-19       Impact factor: 5.640

10.  Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses.

Authors:  Kasandra Bélanger; Mathieu Savoie; María Carla Rosales Gerpe; Jean-François Couture; Marc-André Langlois
Journal:  Nucleic Acids Res       Date:  2013-06-12       Impact factor: 16.971

View more
  1 in total

1.  Molecular Biology and Diversification of Human Retroviruses.

Authors:  Morgan E Meissner; Nathaniel Talledge; Louis M Mansky
Journal:  Front Virol       Date:  2022-06-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.